{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=77", "query": { "intervention": "PLACEBO", "page": 77 }, "page_size": 10 }, "pagination": { "page": 77, "page_size": 10, "total_count": 33137, "total_pages": 3314, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=78&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=76&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T14:30:59.402Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04478266", "title": "Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Amcenestrant-matching placebo", "type": "DRUG" }, { "name": "SAR439859", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Letrozole-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1068, "start_date": "2020-10-14", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 45, "location_summary": "Daphne, Alabama • Glendale, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04478266" }, { "nct_id": "NCT01530022", "title": "Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Lacosamide (LCM)", "type": "DRUG" }, { "name": "Carbamazepine Immediate Release (CBZ-IR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2012-05", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-01-24", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Overland Park, Kansas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01530022" }, { "nct_id": "NCT06058156", "title": "Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "SAR444656 (KT-474)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-11-09", "completion_date": "2025-11-20", "has_results": true, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 7, "location_summary": "Boynton Beach, Florida • Doral, Florida • Hollywood, Florida + 4 more", "locations": [ { "city": "Boynton Beach", "state": "Florida" }, { "city": "Doral", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06058156" }, { "nct_id": "NCT01497431", "title": "Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "No Evidence of Disease", "Prostate Carcinoma" ], "interventions": [ { "name": "Selenium", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Methylselenocysteine", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "MALE", "summary": "40 Years to 80 Years · Male only" }, "enrollment_count": 66, "start_date": "2011-11", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2014-11-26", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 3, "location_summary": "Chicago, Illinois • Buffalo, New York • Nashville, Tennessee", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Buffalo", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497431" }, { "nct_id": "NCT04713202", "title": "Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Carcinoid Syndrome", "Diarrhea" ], "interventions": [ { "name": "Telotristat ethyl", "type": "DRUG" }, { "name": "Peptide Receptor Radionuclide Therapy", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Chandrikha Chandrasekhara", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-03-03", "completion_date": "2024-02", "has_results": false, "last_update_posted_date": "2023-02-10", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04713202" }, { "nct_id": "NCT04551053", "title": "To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post Essential Thrombocythemia Myelofibrosis", "Post Polycythemia Vera Myelofibrosis" ], "interventions": [ { "name": "parsaclisib", "type": "DRUG" }, { "name": "ruxolitinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2021-05-26", "completion_date": "2024-08-21", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 35, "location_summary": "Berkeley, California • Fresno, California • Los Angeles, California + 27 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551053" }, { "nct_id": "NCT00854737", "title": "Cytidine and Omega-3 Fatty Acids in Bipolar Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "cytidine", "type": "DIETARY_SUPPLEMENT" }, { "name": "omega-3 fatty acids", "type": "DIETARY_SUPPLEMENT" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Mclean Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 90, "start_date": "2004-07", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2012-04-20", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 2, "location_summary": "Belmont, Massachusetts • Neptune City, New Jersey", "locations": [ { "city": "Belmont", "state": "Massachusetts" }, { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00854737" }, { "nct_id": "NCT03530345", "title": "Efficacy and Safety of Intravenous Neridronic Acid in CRPS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Complex Regional Pain Syndrome (CRPS)" ], "interventions": [ { "name": "Neridronic acid 100 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grünenthal GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2018-05-30", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2020-08-06", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 39, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03530345" }, { "nct_id": "NCT00556075", "title": "Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "Proellex 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Proellex 50 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "48 Years", "sex": "FEMALE", "summary": "18 Years to 48 Years · Female only" }, "enrollment_count": 67, "start_date": "2007-11", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2014-08-25", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 17, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "San Ramon", "state": "California" }, { "city": "Lake Worth", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00556075" }, { "nct_id": "NCT01254175", "title": "Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Parainfluenza Virus 3, Human" ], "interventions": [ { "name": "rHPIV3cp45 Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "36 Months", "sex": "ALL", "summary": "6 Months to 36 Months" }, "enrollment_count": 28, "start_date": "2010-12", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2014-12-03", "last_synced_at": "2026-11-03T14:30:59.402Z", "location_count": 7, "location_summary": "Long Beach, California • San Diego, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01254175" } ] }